0
Summaries for Patients |

Salsalate for Type 2 Diabetes Mellitus FREE

[+] Article and Author Information

The full report is titled “Salicylate (Salsalate) in Patients With Type 2 Diabetes. A Randomized Trial.” It is in the 2 July 2013 issue of Annals of Internal Medicine (volume 159, pages 1-12). The authors are A.B. Goldfine, V. Fonseca, K.A. Jablonski, Y.D.I. Chen, L. Tipton, M.A. Staten, and S.E. Shoelson, for the Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.

Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.


Ann Intern Med. 2013;159(1):I-32. doi:10.7326/0003-4819-159-1-201307020-00001
Text Size: A A A

What is the problem and what is known about it so far?

Patients with type 2 diabetes mellitus (T2DM) have elevated blood sugar levels, which, if not controlled, lead to both acute and long-term health problems. Many patients continue to have inadequately controlled blood sugar levels even after dietary changes, exercise, or drug therapy.

Salsalate is a drug that has been used for pain treatment for decades. Chemically, it is related to aspirin. Some early evidence suggests that it may lower blood sugar levels in patients with T2DM.

Why did the researchers do this particular study?

To find out whether salsalate can lower blood sugar levels in patients with T2DM and to monitor for possible side effects.

How was the study done?

Patients with established T2DM who were already treated with exercise, dietary changes, or drug therapies (but not insulin) but still had inadequate blood sugar control were invited to participate. Participants were randomly assigned to receive salsalate or placebo once a day. Patients continued their other medications for treatment of T2DM, and their blood sugar as well as other blood levels were observed for 1 year. They were also monitored for side effects. Other changes to their treatments were allowed if needed.

What did the researchers find?

During the 1-year study, markers of blood sugar control were improved in the participants who received salsalate compared with those who received placebo pills. In addition, overall, the participants receiving salsalate were receiving fewer other medications for treatment of T2DM, whereas participants receiving placebo were more likely to require more medications. Blood work results suggested that salsalate reduced inflammation in the body, which may be one way that the drug improved blood sugar control. Some increases in weight and blood lipid levels were seen, as was a marker of reduced kidney function that reversed after salsalate was stopped.

What were the limitations of the study?

The study lasted only 1 year and could not more definitively assess whether the changes in weight, blood pressure, lipid levels, and kidney function posed any long-term problem.

What are the implications of the study?

Salsalate may be a useful treatment of patients with T2DM. Further, longer-term studies are ongoing to assess this possibility.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)